

**FOOD AND DRUG ADMINISTRATION (FDA)**

Center for Drug Evaluation and Research (CDER)

*Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting*  
FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)  
10903 New Hampshire Avenue, Silver Spring, Maryland  
November 13, 2019

**QUESTIONS**

---

1. **DISCUSSION:** Discuss whether empagliflozin 2.5 mg as an adjunct to insulin provides benefit for adult patients with type 1 diabetes. Discuss your views of the clinical meaningfulness of the small HbA1c reduction as well as other endpoints studied to evaluate benefits of empagliflozin 2.5 mg including body weight and blood pressure.
2. **DISCUSSION:** Discuss your level of concern about the risk of diabetic ketoacidosis (DKA) with the use of empagliflozin 2.5 mg in type 1 diabetes patients. Discuss your level of confidence in the ability of the available safety database to accurately characterize the DKA risk given the small number of events observed in a single trial that is only 26 weeks in duration. Discuss your level of confidence in the reliability of the adjudication process to assess DKA risk, including the clinical meaningfulness of the adjudication categories, and the applicability of extrapolating risk management in a clinical trial setting to real world use.
3. **DISCUSSION:** Discuss the overall benefit/risk profile of empagliflozin 2.5 mg as an adjunct to insulin therapy for the treatment of adult patients with type 1 diabetes. Discuss the sufficiency of the demonstrated benefit(s) in light of the uncertainties around the DKA risk and other risks of the drug.
4. **VOTE:** Do the available data suggest that the benefits outweigh the risks and support approval of empagliflozin 2.5 mg, administered orally once daily, as an adjunct to insulin to improve glycemic control in adults with type 1 diabetes mellitus?
  - a. If yes, please explain your rationale and comment on whether any additional studies should be required after approval.
  - b. If no, please describe what further data you believe the applicant should provide to establish a favorable benefit risk profile to support approval.